Kick off 2026 with a competitive edge at PACK EXPO East. Register now!
Get a jump on your 2026 goals at PACK EXPO East. Put projects in motion, accelerate timelines and solve challenges—all in one trip to Philadelphia.

Eclipsing the competition

Recently approved by the U.S. Food and Drug Administration for OTC sales, SmithKline Beecham's new Tagamet HB is one of the first "Acid blocker" products to reach the re-tail market.

Pw 25899 Recappbythe 9

Introduced nationally last month, powerful folding carton gra-phics provide quite a departure from the predominately white ap-proach typically taken with drug products. "We found that this design did a great job of catching the consumer's eye," says Paul Madzik, senior product manager at Philadelphia, PA-based SmithKline Beecham. "We think it communicates the right image for Tagamet: It's a breakthrough in advanced medicine, a revolutionary and very unique product." Created by SBG Partners (San Francisco, CA), a solar eclipse design alludes to the product's ability to prevent acids from forming in the stomach. "We were looking for a graphic symbol that could quickly signal how powerful Tagamet HB is in reducing heartburn," explained Flavio Gomez, senior managing partner of SBG Partners. To further differentiate the package, the eclipse is positioned against a navy blue background. At press time, supplier information was not available from SmithKline. Tagamet HB is available in 16-, 32- and 64-count packages.

Annual Outlook Report: Sustainability
The road ahead for CPGs in 2025 and beyond—Packaging World editors review key findings from a survey of 88 brand owners, CPG, and FMCG readers.
Download Now
Annual Outlook Report: Sustainability
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? Packaging World editors explore the survey responses from 118 brand owners, CPG, and FMCG Packaging World readers for its new Annual Outlook Report.
Download
Annual Outlook Report: Automation & Robotics